Loading...
Explore More at wakehealth.edu

Clinical and Translational Science Institute

Keywords
Last Name

Maurizio Bendandi

TitleProfessor
InstitutionWake Forest School of Medicine
DepartmentInternal Medicine - Hematology and Oncology
Address
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Soldevilla MM, Hervas S, Villanueva H, Lozano T, Rabal O, Oyarzabal J, Lasarte JJ, Bendandi M, Inoges S, López-Díaz de Cerio A, Pastor F. Identification of LAG3 high affinity aptamers by HT-SELEX and Conserved Motif Accumulation (CMA). PLoS One. 2017; 12(9):e0185169. PMID: 28934318.
      View in: PubMed
    2. Inogés S, Tejada S, de Cerio AL, Gállego Pérez-Larraya J, Espinós J, Idoate MA, Domínguez PD, de Eulate RG, Aristu J, Bendandi M, Pastor F, Alonso M, Andreu E, Cardoso FP, Valle RD. A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients. J Transl Med. 2017 05 12; 15(1):104. PMID: 28499389.
      View in: PubMed
    3. Soldevilla MM, Villanueva H, Casares N, Lasarte JJ, Bendandi M, Inoges S, López-Díaz de Cerio A, Pastor F. MRP1-CD28 bi-specific oligonucleotide aptamers: target costimulation to drug-resistant melanoma cancer stem cells. Oncotarget. 2016 Apr 26; 7(17):23182-96. PMID: 26992239.
      View in: PubMed
    4. Lozano T, Soldevilla MM, Casares N, Villanueva H, Bendandi M, Lasarte JJ, Pastor F. Targeting inhibition of Foxp3 by a CD28 2'-Fluro oligonucleotide aptamer conjugated to P60-peptide enhances active cancer immunotherapy. Biomaterials. 2016 Jun; 91:73-80. PMID: 26999456.
      View in: PubMed
    5. Hervas-Stubbs S, Soldevilla MM, Villanueva H, Mancheño U, Bendandi M, Pastor F. Identification of TIM3 2'-fluoro oligonucleotide aptamer by HT-SELEX for cancer immunotherapy. Oncotarget. 2016 Jan 26; 7(4):4522-30. PMID: 26683225.
      View in: PubMed
    6. Tusé D, Ku N, Bendandi M, Becerra C, Collins R, Langford N, Sancho SI, López-Díaz de Cerio A, Pastor F, Kandzia R, Thieme F, Jarczowski F, Krause D, Ma JK, Pandya S, Klimyuk V, Gleba Y, Butler-Ransohoff JE. Clinical Safety and Immunogenicity of Tumor-Targeted, Plant-Made Id-KLH Conjugate Vaccines for Follicular Lymphoma. Biomed Res Int. 2015; 2015:648143. PMID: 26425548.
      View in: PubMed
    7. Soldevilla MM, Villanueva H, Bendandi M, Inoges S, López-Díaz de Cerio A, Pastor F. 2-fluoro-RNA oligonucleotide CD40 targeted aptamers for the control of B lymphoma and bone-marrow aplasia. Biomaterials. 2015 Oct; 67:274-85. PMID: 26231918.
      View in: PubMed
    8. Inoges S, de Cerio AL, Villanueva H, Pastor F, Bendandi M. Idiotype vaccine production using hybridoma technology. Methods Mol Biol. 2014; 1139:367-87. PMID: 24619694.
      View in: PubMed
    9. Pastor F, Soldevilla MM, Villanueva H, Kolonias D, Inoges S, de Cerio AL, Kandzia R, Klimyuk V, Gleba Y, Gilboa E, Bendandi M. CD28 aptamers as powerful immune response modulators. Mol Ther Nucleic Acids. 2013 Jun 11; 2:e98. PMID: 23756353.
      View in: PubMed
    10. Valle RD, de Cerio AL, Inoges S, Tejada S, Pastor F, Villanueva H, Gallego J, Espinos J, Aristu J, Idoate MA, Andreu E, Bendandi M. Dendritic cell vaccination in glioblastoma after fluorescence-guided resection. World J Clin Oncol. 2012 Nov 10; 3(11):142-9. PMID: 23293753.
      View in: PubMed
    11. de Cerio AL, Inogés S, Ai WZ, Villanueva H, Pastor F, Soldevilla MM, Soria E, Bendandi M. Successful idiotypic vaccination following stem cell allotransplant in lymphoma. Leuk Lymphoma. 2013 Apr; 54(4):881-4. PMID: 22897725.
      View in: PubMed
    12. Villanueva H, de Cerio AL, Inoges S, Pastor F, Soldevilla MM, Bendandi M. BiovaxID®: a customized idiotype vaccine for the treatment of B-cell lymphoma. Expert Rev Vaccines. 2011 Dec; 10(12):1661-9. PMID: 22085168.
      View in: PubMed
    13. Inoges S, de Cerio AL, Villanueva H, Pastor F, Soria E, Bendandi M. Idiotype vaccines for lymphoma: Potential factors predicting the induction of immune responses. World J Clin Oncol. 2011 Jun 10; 2(6):237-44. PMID: 21773074.
      View in: PubMed
    14. Inogés S, de Cerio AL, Villanueva H, Soria E, Pastor F, Bendandi M. Idiotype vaccines for lymphoma therapy. Expert Rev Vaccines. 2011 Jun; 10(6):801-9. PMID: 21692701.
      View in: PubMed
    15. Inoges S, Lopez-Diaz de Cerio A, Sampol A, Nieto J, Soria E, Villanueva H, Pastor F, Bendandi M. Stem cell transplant and idiotypic vaccination for B-cell malignancies. Curr Top Med Chem. 2011; 11(13):1653-60. PMID: 21446912.
      View in: PubMed
    16. Bendandi M. Hybridoma-Derived Idiotype Vaccine for Lymphoma: Approval Must Wait. Pharmaceuticals (Basel). 2010 Mar 15; 3(3):667-678. PMID: 27713273.
      View in: PubMed
    17. Bendandi M. Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures. Nat Rev Cancer. 2009 Sep; 9(9):675-81. PMID: 19701243.
      View in: PubMed
    18. García-Muñoz R, Panizo C, Bendandi M, Llorente L. Autoimmunity and lymphoma: is mantle cell lymphoma a mistake of the receptor editing mechanism? Leuk Res. 2009 Nov; 33(11):1437-9. PMID: 19523686.
      View in: PubMed
    19. Inoges S, Lopez-Diaz de Cerio A, Zabalegui N, Soria E, Villanueva H, Panizo C, Rodriguez-Caballero A, Suarez L, Pastor F, Rodriguez-Calvillo M, Orfao A, Bendandi M. Prolonged idiotypic vaccination against follicular lymphoma. Leuk Lymphoma. 2009 Jan; 50(1):47-53. PMID: 19152172.
      View in: PubMed
    20. Bendandi M. Aiming at a curative strategy for follicular lymphoma. CA Cancer J Clin. 2008 Sep-Oct; 58(5):305-17. PMID: 18755938.
      View in: PubMed
    21. García-Muñoz R, Rodriguez-Otero P, Pegenaute C, Merino J, Jakes-Okampo J, Llorente L, Bendandi M, Panizo C. Splenic marginal zone lymphoma with Evans' syndrome, autoimmunity, and peripheral gamma/delta T cells. Ann Hematol. 2009 Feb; 88(2):177-8. PMID: 18665362.
      View in: PubMed
    22. Martinez-Forero I, Garcia-Munoz R, Martinez-Pasamar S, Inoges S, Lopez-Diaz de Cerio A, Palacios R, Sepulcre J, Moreno B, Gonzalez Z, Fernandez-Diez B, Melero I, Bendandi M, Villoslada P. IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis. Eur J Immunol. 2008 Feb; 38(2):576-86. PMID: 18200504.
      View in: PubMed
    23. Rodríguez J, Conde E, Gutiérrez A, Lahuerta JJ, Arranz R, Sureda A, Zuazu J, Fernández de Sevilla A, Bendandi M, Solano C, León A, Varela MR, Caballero MD. The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma. Haematologica. 2007 Aug; 92(8):1067-74. PMID: 17640855.
      View in: PubMed
    24. Rodríguez J, Conde E, Gutiérrez A, Arranz R, León A, Marín J, Bendandi M, Albo C, Caballero MD. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur J Haematol. 2007 Jul; 79(1):32-8. PMID: 17598836.
      View in: PubMed
    25. Arina A, Murillo O, Dubrot J, Azpilikueta A, Alfaro C, Pérez-Gracia JL, Bendandi M, Palencia B, Hervás-Stubbs S, Melero I. Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer. Expert Opin Biol Ther. 2007 May; 7(5):599-615. PMID: 17477799.
      View in: PubMed
    26. Redondo P, del Olmo J, López-Diaz de Cerio A, Inoges S, Marquina M, Melero I, Bendandi M. Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions. J Invest Dermatol. 2007 Jul; 127(7):1673-80. PMID: 17380112.
      View in: PubMed
    27. Radcliffe CM, Arnold JN, Suter DM, Wormald MR, Harvey DJ, Royle L, Mimura Y, Kimura Y, Sim RB, Inogès S, Rodriguez-Calvillo M, Zabalegui N, de Cerio AL, Potter KN, Mockridge CI, Dwek RA, Bendandi M, Rudd PM, Stevenson FK. Human follicular lymphoma cells contain oligomannose glycans in the antigen-binding site of the B-cell receptor. J Biol Chem. 2007 Mar 09; 282(10):7405-15. PMID: 17197448.
      View in: PubMed
    28. Inogès S, Rodrìguez-Calvillo M, Zabalegui N, Lòpez-Dìaz de Cerio A, Villanueva H, Soria E, Suárez L, Rodríguez-Caballero A, Pastor F, García-Muñóz R, Panizo C, Pèrez-Calvo J, Melero I, Rocha E, Orfao A, Bendandi M. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst. 2006 Sep 20; 98(18):1292-301. PMID: 16985248.
      View in: PubMed
    29. Melero I, Arina A, Murillo O, Dubrot J, Alfaro C, Pérez-Gracia JL, Bendandi M, Hervás-Stubbs S. Immunogenic cell death and cross-priming are reaching the clinical immunotherapy arena. Clin Cancer Res. 2006 Apr 15; 12(8):2385-9. PMID: 16638842.
      View in: PubMed
    30. Bendandi M. Clinical benefit of idiotype vaccines: too many trials for a clever demonstration? Rev Recent Clin Trials. 2006 Jan; 1(1):67-74. PMID: 18393782.
      View in: PubMed
    31. Bendandi M, Rodríguez-Calvillo M, Inogés S, López-Díaz de Cerio A, Pérez-Simón JA, Rodríguez-Caballero A, García-Montero A, Almeida J, Zabalegui N, Giraldo P, San Miguel J, Orfao A. Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation. Leuk Lymphoma. 2006 Jan; 47(1):29-37. PMID: 16321824.
      View in: PubMed
    32. Mazzolini G, Alfaro C, Sangro B, Feijoó E, Ruiz J, Benito A, Tirapu I, Arina A, Sola J, Herraiz M, Lucena F, Olagüe C, Subtil J, Quiroga J, Herrero I, Sádaba B, Bendandi M, Qian C, Prieto J, Melero I. Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. J Clin Oncol. 2005 Feb 10; 23(5):999-1010. PMID: 15598979.
      View in: PubMed
    33. Rodríguez-Calvillo M, Inogés S, López-Díaz de Cerio A, Zabalegui N, Villanueva H, Bendandi M. Variations in "rescuability" of immunoglobulin molecules from different forms of human lymphoma: implications for anti-idiotype vaccine development. Crit Rev Oncol Hematol. 2004 Oct; 52(1):1-7. PMID: 15363462.
      View in: PubMed
    34. Panizo C, Pérez-Salazar M, Bendandi M, Rodríguez-Calvillo M, Boán JF, García-Velloso MJ, Richter J, Rocha E. Positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual Hodgkin's disease mediastinal masses. Leuk Lymphoma. 2004 Sep; 45(9):1829-33. PMID: 15223643.
      View in: PubMed
    35. Zabalegui N, de Cerio AL, Inogés S, Rodríguez-Calvillo M, Pérez-Calvo J, Hernández M, García-Foncillas J, Martín-Algarra S, Rocha E, Bendandi M. Acquired potential N-glycosylation sites within the tumor-specific immunoglobulin heavy chains of B-cell malignancies. Haematologica. 2004 May; 89(5):541-6. PMID: 15136216.
      View in: PubMed
    36. Bendandi M. The role of idiotype vaccines in the treatment of human B-cell malignancies. Expert Rev Vaccines. 2004 Apr; 3(2):163-70. PMID: 15056042.
      View in: PubMed
    37. Inogés S, Rodríguez-Calvillo M, López-Díaz de Cerio A, Zabalegui N, Pérez-Calvo J, Panizo C, Hernandez M, Cuesta B, Rocha E, Bendandi M. Feasibility of idiotype vaccination in relapsed B-cell malignancies. Haematologica. 2003 Dec; 88(12):1438-40. PMID: 14688006.
      View in: PubMed
    38. Murillo O, Arina A, Tirapu I, Alfaro C, Mazzolini G, Palencia B, López-Diaz De Cerio A, Prieto J, Bendandi M, Melero I. Potentiation of therapeutic immune responses against malignancies with monoclonal antibodies. Clin Cancer Res. 2003 Nov 15; 9(15):5454-64. PMID: 14654524.
      View in: PubMed
    39. Pession A, Tonelli R, Canderan G, Bendandi M, Rosolen A, Basso K, Basso G, Locatelli F, Zabalegui N, Paolucci G. Non-radiolabelled PCR consensus primers and automatic sequencing enable rapid identification of tumor-specific V(H) CDR3 in aggressive B-cell malignancies. Leuk Lymphoma. 2003 Sep; 44(9):1597-601. PMID: 14565664.
      View in: PubMed
    40. Panizo C, Patiño A, Lecumberri R, Calasanz MJ, Odero MD, Bendandi M, Rocha E. Secondary myelodysplastic syndrome after treatment for promyelocytic leukemia: clinical and genetic features of two cases. Cancer Genet Cytogenet. 2003 Jun; 143(2):178-81. PMID: 12781455.
      View in: PubMed
    41. Arina A, Tirapu I, Alfaro C, Rodríguez-Calvillo M, Mazzolini G, Inogés S, López A, Feijoo E, Bendandi M, Melero I. Clinical implications of antigen transfer mechanisms from malignant to dendritic cells. exploiting cross-priming. Exp Hematol. 2002 Dec; 30(12):1355-64. PMID: 12482496.
      View in: PubMed
    42. Federico M, Zinzani PL, Frassoldati A, Vinceti M, Modè A, Annino L, Chisesi T, Pagnucco G, Invernizzi R, Spriano M, Resegotti L, Bendandi M, Damasio EE. Risk of second cancer in patients with hairy cell leukemia: long-term follow-up. J Clin Oncol. 2002 Feb 01; 20(3):638-46. PMID: 11821443.
      View in: PubMed
    Bendandi's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _